1.1 	A bill for an act
1.2 	relating to public safety; rescheduling marijuana and tetrahydrocannabinols;
1.3 	amending Minnesota Statutes 2018, section 152.02, subdivisions 2, 3.
1.4 	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.5 	Section 1. Minnesota Statutes 2018, section 152.02, subdivision 2, is amended to read:
1.6 		Subd. 2.Schedule I. (a) Schedule I consists of the substances listed in this subdivision.
1.7 	(b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the 
1.8 	following substances, including their analogs, isomers, esters, ethers, salts, and salts of 
1.9 	isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters, ethers, 
1.10 	and salts is possible:
1.11 	(1) acetylmethadol;
1.12 	(2) allylprodine;
1.13 	(3) alphacetylmethadol (except levo-alphacetylmethadol, also known as levomethadyl 
1.14 	acetate);
1.15 	(4) alphameprodine;
1.16 	(5) alphamethadol;
1.17 	(6) alpha-methylfentanyl benzethidine;
1.18 	(7) betacetylmethadol;
1.19 	(8) betameprodine;
1.20 	(9) betamethadol;
2.1 	(10) betaprodine;
2.2 	(11) clonitazene;
2.3 	(12) dextromoramide;
2.4 	(13) diampromide;
2.5 	(14) diethyliambutene;
2.6 	(15) difenoxin;
2.7 	(16) dimenoxadol;
2.8 	(17) dimepheptanol;
2.9 	(18) dimethyliambutene;
2.10 	(19) dioxaphetyl butyrate;
2.11 	(20) dipipanone;
2.12 	(21) ethylmethylthiambutene;
2.13 	(22) etonitazene;
2.14 	(23) etoxeridine;
2.15 	(24) furethidine;
2.16 	(25) hydroxypethidine;
2.17 	(26) ketobemidone;
2.18 	(27) levomoramide;
2.19 	(28) levophenacylmorphan;
2.20 	(29) 3-methylfentanyl;
2.21 	(30) acetyl-alpha-methylfentanyl;
2.22 	(31) alpha-methylthiofentanyl;
2.23 	(32) benzylfentanyl beta-hydroxyfentanyl;
2.24 	(33) beta-hydroxy-3-methylfentanyl;
2.25 	(34) 3-methylthiofentanyl;
2.26 	(35) thenylfentanyl;
2.27 	(36) thiofentanyl;
3.1 	(37) para-fluorofentanyl;
3.2 	(38) morpheridine;
3.3 	(39) 1-methyl-4-phenyl-4-propionoxypiperidine;
3.4 	(40) noracymethadol;
3.5 	(41) norlevorphanol;
3.6 	(42) normethadone;
3.7 	(43) norpipanone;
3.8 	(44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
3.9 	(45) phenadoxone;
3.10 	(46) phenampromide;
3.11 	(47) phenomorphan;
3.12 	(48) phenoperidine;
3.13 	(49) piritramide;
3.14 	(50) proheptazine;
3.15 	(51) properidine;
3.16 	(52) propiram;
3.17 	(53) racemoramide;
3.18 	(54) tilidine;
3.19 	(55) trimeperidine;
3.20 	(56) N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);
3.21 	(57) 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-
3.22 	methylbenzamide(U47700);
3.23 	(58) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide(furanylfentanyl); 
3.24 	and
3.25 	(59) 4-(4-bromophenyl)-4-dimethylamino-1-phenethylcyclohexanol (bromadol).
3.26 	(c) Opium derivatives. Any of the following substances, their analogs, salts, isomers, 
3.27 	and salts of isomers, unless specifically excepted or unless listed in another schedule, 
3.28 	whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
4.1 	(1) acetorphine;
4.2 	(2) acetyldihydrocodeine;
4.3 	(3) benzylmorphine;
4.4 	(4) codeine methylbromide;
4.5 	(5) codeine-n-oxide;
4.6 	(6) cyprenorphine;
4.7 	(7) desomorphine;
4.8 	(8) dihydromorphine;
4.9 	(9) drotebanol;
4.10 	(10) etorphine;
4.11 	(11) heroin;
4.12 	(12) hydromorphinol;
4.13 	(13) methyldesorphine;
4.14 	(14) methyldihydromorphine;
4.15 	(15) morphine methylbromide;
4.16 	(16) morphine methylsulfonate;
4.17 	(17) morphine-n-oxide;
4.18 	(18) myrophine;
4.19 	(19) nicocodeine;
4.20 	(20) nicomorphine;
4.21 	(21) normorphine;
4.22 	(22) pholcodine; and
4.23 	(23) thebacon.
4.24 	(d) Hallucinogens. Any material, compound, mixture or preparation which contains any 
4.25 	quantity of the following substances, their analogs, salts, isomers (whether optical, positional, 
4.26 	or geometric), and salts of isomers, unless specifically excepted or unless listed in another 
4.27 	schedule, whenever the existence of the analogs, salts, isomers, and salts of isomers is 
4.28 	possible:
5.1 	(1) methylenedioxy amphetamine;
5.2 	(2) methylenedioxymethamphetamine;
5.3 	(3) methylenedioxy-N-ethylamphetamine (MDEA);
5.4 	(4) n-hydroxy-methylenedioxyamphetamine;
5.5 	(5) 4-bromo-2,5-dimethoxyamphetamine (DOB);
5.6 	(6) 2,5-dimethoxyamphetamine (2,5-DMA);
5.7 	(7) 4-methoxyamphetamine;
5.8 	(8) 5-methoxy-3, 4-methylenedioxyamphetamine;
5.9 	(9) alpha-ethyltryptamine;
5.10 	(10) bufotenine;
5.11 	(11) diethyltryptamine;
5.12 	(12) dimethyltryptamine;
5.13 	(13) 3,4,5-trimethoxyamphetamine;
5.14 	(14) 4-methyl-2, 5-dimethoxyamphetamine (DOM);
5.15 	(15) ibogaine;
5.16 	(16) lysergic acid diethylamide (LSD);
5.17 	(17) mescaline;
5.18 	(18) parahexyl;
5.19 	(19) N-ethyl-3-piperidyl benzilate;
5.20 	(20) N-methyl-3-piperidyl benzilate;
5.21 	(21) psilocybin;
5.22 	(22) psilocyn;
5.23 	(23) tenocyclidine (TPCP or TCP);
5.24 	(24) N-ethyl-1-phenyl-cyclohexylamine (PCE);
5.25 	(25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy);
5.26 	(26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);
5.27 	(27) 4-chloro-2,5-dimethoxyamphetamine (DOC);
6.1 	(28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);
6.2 	(29) 4-iodo-2,5-dimethoxyamphetamine (DOI);
6.3 	(30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);
6.4 	(31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);
6.5 	(32) 4-methyl-2,5-dimethoxyphenethylamine (2C-D);
6.6 	(33) 4-ethyl-2,5-dimethoxyphenethylamine (2C-E);
6.7 	(34) 4-iodo-2,5-dimethoxyphenethylamine (2C-I);
6.8 	(35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);
6.9 	(36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);
6.10 	(37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);
6.11 	(38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine 
6.12 	(2-CB-FLY);
6.13 	(39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);
6.14 	(40) alpha-methyltryptamine (AMT);
6.15 	(41) N,N-diisopropyltryptamine (DiPT);
6.16 	(42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);
6.17 	(43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);
6.18 	(44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);
6.19 	(45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);
6.20 	(46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);
6.21 	(47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
6.22 	(48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);
6.23 	(49) 5-methoxy-α-methyltryptamine (5-MeO-AMT);
6.24 	(50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
6.25 	(51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);
6.26 	(52) 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);
6.27 	(53) 5-methoxy-α-ethyltryptamine (5-MeO-AET);
7.1 	(54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);
7.2 	(55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);
7.3 	(56) 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT);
7.4 	(57) methoxetamine (MXE);
7.5 	(58) 5-iodo-2-aminoindane (5-IAI);
7.6 	(59) 5,6-methylenedioxy-2-aminoindane (MDAI);
7.7 	(60) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe);
7.8 	(61) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe);
7.9 	(62) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe);
7.10 	(63) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
7.11 	(64) 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2);
7.12 	(65) N,N-Dipropyltryptamine (DPT);
7.13 	(66) 3-[1-(Piperidin-1-yl)cyclohexyl]phenol (3-HO-PCP);
7.14 	(67) N-ethyl-1-(3-methoxyphenyl)cyclohexanamine (3-MeO-PCE);
7.15 	(68) 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo);
7.16 	(69) 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine (methoxydine, 4-MeO-PCP);
7.17 	(70) 2-(2-Chlorophenyl)-2-(ethylamino)cyclohexan-1-one (N-Ethylnorketamine, 
7.18 	ethketamine, NENK);
7.19 	(71) methylenedioxy-N,N-dimethylamphetamine (MDDMA);
7.20 	(72) 3-(2-Ethyl(methyl)aminoethyl)-1H-indol-4-yl (4-AcO-MET); and
7.21 	(73) 2-Phenyl-2-(methylamino)cyclohexanone (deschloroketamine).
7.22 	(e) Peyote. All parts of the plant presently classified botanically as Lophophora williamsii 
7.23 	Lemaire, whether growing or not, the seeds thereof, any extract from any part of the plant, 
7.24 	and every compound, manufacture, salts, derivative, mixture, or preparation of the plant, 
7.25 	its seeds or extracts. The listing of peyote as a controlled substance in Schedule I does not 
7.26 	apply to the nondrug use of peyote in bona fide religious ceremonies of the American Indian 
7.27 	Church, and members of the American Indian Church are exempt from registration. Any 
7.28 	person who manufactures peyote for or distributes peyote to the American Indian Church, 
8.1 	however, is required to obtain federal registration annually and to comply with all other 
8.2 	requirements of law.
8.3 	(f) Central nervous system depressants. Unless specifically excepted or unless listed in 
8.4 	another schedule, any material compound, mixture, or preparation which contains any 
8.5 	quantity of the following substances, their analogs, salts, isomers, and salts of isomers 
8.6 	whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
8.7 	(1) mecloqualone;
8.8 	(2) methaqualone;
8.9 	(3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;
8.10 	(4) flunitrazepam; and
8.11 	(5) 2-(2-Methoxyphenyl)-2-(methylamino)cyclohexanone (2-MeO-2-deschloroketamine, 
8.12 	methoxyketamine).
8.13 	(g) Stimulants. Unless specifically excepted or unless listed in another schedule, any 
8.14 	material compound, mixture, or preparation which contains any quantity of the following 
8.15 	substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the 
8.16 	analogs, salts, isomers, and salts of isomers is possible:
8.17 	(1) aminorex;
8.18 	(2) cathinone;
8.19 	(3) fenethylline;
8.20 	(4) methcathinone;
8.21 	(5) methylaminorex;
8.22 	(6) N,N-dimethylamphetamine;
8.23 	(7) N-benzylpiperazine (BZP);
8.24 	(8) methylmethcathinone (mephedrone);
8.25 	(9) 3,4-methylenedioxy-N-methylcathinone (methylone);
8.26 	(10) methoxymethcathinone (methedrone);
8.27 	(11) methylenedioxypyrovalerone (MDPV);
8.28 	(12) 3-fluoro-N-methylcathinone (3-FMC);
8.29 	(13) methylethcathinone (MEC);
9.1 	(14) 1-benzofuran-6-ylpropan-2-amine (6-APB);
9.2 	(15) dimethylmethcathinone (DMMC);
9.3 	(16) fluoroamphetamine;
9.4 	(17) fluoromethamphetamine;
9.5 	(18) α-methylaminobutyrophenone (MABP or buphedrone);
9.6 	(19) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone);
9.7 	(20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);
9.8 	(21) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one (naphthylpyrovalerone or 
9.9 	naphyrone);
9.10 	(22) (alpha-pyrrolidinopentiophenone (alpha-PVP);
9.11 	(23) (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone (4-Me-PHP or MPHP);
9.12 	(24) 2-(1-pyrrolidinyl)-hexanophenone (Alpha-PHP);
9.13 	(25) 4-methyl-N-ethylcathinone (4-MEC);
9.14 	(26) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);
9.15 	(27) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
9.16 	(28) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone);
9.17 	(29) 4-fluoro-N-methylcathinone (4-FMC);
9.18 	(30) 3,4-methylenedioxy-N-ethylcathinone (ethylone);
9.19 	(31) alpha-pyrrolidinobutiophenone (α-PBP);
9.20 	(32) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB);
9.21 	(33) 1-phenyl-2-(1-pyrrolidinyl)-1-heptanone (PV8);
9.22 	(34) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB);
9.23 	(35) 4-methyl-alpha-ethylaminopentiophenone (4-MEAPP);
9.24 	(36) 4'-chloro-alpha-pyrrolidinopropiophenone (4'-chloro-PPP);
9.25 	(37) 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)butan-1-one (dibutylone, bk-DMBDB);
9.26 	(38) 1-(3-chlorophenyl) piperazine (meta-chlorophenylpiperazine or mCPP); and
9.27 	(39) any other substance, except bupropion or compounds listed under a different 
9.28 	schedule, that is structurally derived from 2-aminopropan-1-one by substitution at the 
10.1 	1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the 
10.2 	compound is further modified in any of the following ways:
10.3 	(i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, 
10.4 	haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring 
10.5 	system by one or more other univalent substituents;
10.6 	(ii) by substitution at the 3-position with an acyclic alkyl substituent;
10.7 	(iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or 
10.8 	methoxybenzyl groups; or
10.9 	(iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.
10.10 	(h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless specifically 
10.11 	excepted or unless listed in another schedule, any natural or synthetic material, compound, 
10.12 	mixture, or preparation that contains any quantity of the following substances, their analogs, 
10.13 	isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence 
10.14 	of the isomers, esters, ethers, or salts is possible:
10.15 	(1) marijuana;
10.16 	(2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, synthetic 
10.17 	equivalents of the substances contained in the cannabis plant or in the resinous extractives 
10.18 	of the plant, or synthetic substances with similar chemical structure and pharmacological 
10.19 	activity to those substances contained in the plant or resinous extract, including, but not 
10.20 	limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans tetrahydrocannabinol, and 3,4 
10.21 	cis or trans tetrahydrocannabinol;
10.22 	(3) (h) Synthetic cannabinoids, including the following substances:
10.23 	(i) (1) Naphthoylindoles, which are any compounds containing a 3-(1-napthoyl)indole 
10.24 	structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, 
10.25 	alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
10.26 	2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any 
10.27 	extent and whether or not substituted in the naphthyl ring to any extent. Examples of 
10.28 	naphthoylindoles include, but are not limited to:
10.29 	(A) (i) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);
10.30 	(B) (ii) 1-Butyl-3-(1-naphthoyl)indole (JWH-073);
10.31 	(C) (iii) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);
10.32 	(D) (iv) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);
11.1 	(E) (v) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);
11.2 	(F) (vi) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);
11.3 	(G) (vii) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);
11.4 	(H) (viii) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);
11.5 	(I) (ix) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);
11.6 	(J) (x) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).
11.7 	(ii) (2) Napthylmethylindoles, which are any compounds containing a 
11.8 	1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the 
11.9 	indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
11.10 	1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further 
11.11 	substituted in the indole ring to any extent and whether or not substituted in the naphthyl 
11.12 	ring to any extent. Examples of naphthylmethylindoles include, but are not limited to:
11.13 	(A) (i) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);
11.14 	(B) (ii) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane (JWH-184).
11.15 	(iii) (3) Naphthoylpyrroles, which are any compounds containing a 3-(1-naphthoyl)pyrrole 
11.16 	structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, 
11.17 	alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
11.18 	2-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any 
11.19 	extent, whether or not substituted in the naphthyl ring to any extent. Examples of 
11.20 	naphthoylpyrroles include, but are not limited to, 
11.21 	(5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).
11.22 	(iv) (4) Naphthylmethylindenes, which are any compounds containing a 
11.23 	naphthylideneindene structure with substitution at the 3-position of the indene ring by an 
11.24 	alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
11.25 	1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further 
11.26 	substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring 
11.27 	to any extent. Examples of naphthylemethylindenes include, but are not limited to, 
11.28 	E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).
11.29 	(v) (5) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole 
11.30 	structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, 
11.31 	alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
11.32 	2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any 
12.1 	extent, whether or not substituted in the phenyl ring to any extent. Examples of 
12.2 	phenylacetylindoles include, but are not limited to:
12.3 	(A) (i) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);
12.4 	(B) (ii) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
12.5 	(C) (iii) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);
12.6 	(D) (iv) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).
12.7 	(vi) (6) Cyclohexylphenols, which are compounds containing a 
12.8 	2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic 
12.9 	ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
12.10 	1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted 
12.11 	in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include, but are not 
12.12 	limited to:
12.13 	(A) (i) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);
12.14 	(B) (ii) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol 
12.15 	(Cannabicyclohexanol or CP 47,497 C8 homologue);
12.16 	(C) (iii) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl] 
12.17 	-phenol (CP 55,940).
12.18 	(vii) (7) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole 
12.19 	structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, 
12.20 	alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
12.21 	2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any 
12.22 	extent and whether or not substituted in the phenyl ring to any extent. Examples of 
12.23 	benzoylindoles include, but are not limited to:
12.24 	(A) (i) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);
12.25 	(B) (ii) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);
12.26 	(C) (iii) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone 
12.27 	(WIN 48,098 or Pravadoline).
12.28 	(viii) (8) Others specifically named:
12.29 	(A) (i) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) 
12.30 	-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);
13.1 	(B) (ii) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) 
13.2 	-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);
13.3 	(C) (iii) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de] 
13.4 	-1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2);
13.5 	(D) (iv) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);
13.6 	(E) (v) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone 
13.7 	(XLR-11);
13.8 	(F) (vi) 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide 
13.9 	(AKB-48(APINACA));
13.10 	(G) (vii) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide 
13.11 	(5-Fluoro-AKB-48);
13.12 	(H) (viii) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);
13.13 	(I) (ix) 8-quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5-Fluoro 
13.14 	PB-22);
13.15 	(J) (x) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole- 3-carboxamide 
13.16 	(AB-PINACA);
13.17 	(K) (xi) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]- 
13.18 	1H-indazole-3-carboxamide (AB-FUBINACA);
13.19 	(L) (xii) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H- 
13.20 	indazole-3-carboxamide(AB-CHMINACA);
13.21 	(M) (xiii) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3- 
13.22 	methylbutanoate (5-fluoro-AMB);
13.23 	(N) (xiv) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone (THJ-2201);
13.24 	(O) (xv) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone) 
13.25 	(FUBIMINA);
13.26 	(P) (xvi) (7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo 
13.27 	[2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12);
13.28 	(Q) (xvii) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl) 
13.29 	-1H-indole-3-carboxamide (5-fluoro-ABICA);
13.30 	(R) (xviii) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl) 
13.31 	-1H-indole-3-carboxamide;
14.1 	(S) (xix) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl) 
14.2 	-1H-indazole-3-carboxamide;
14.3 	(T) (xx) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido) 
14.4 	-3,3-dimethylbutanoate;
14.5 	(U) (xxi) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1 
14.6 	H-indazole-3-carboxamide (MAB-CHMINACA);
14.7 	(V) (xxii)
14.8 	N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1H-indazole-3-carboxamide 
14.9 	(ADB-PINACA);
14.10 	(W) (xxiii) methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate (FUB-AMB);
14.11 	(X) (xxiv)
14.12 	N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-1-(cyclohexylmethyl)-1H-Indazole-
14.13 	3-carboxamide. (APP-CHMINACA);
14.14 	(Y) (xxv) quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FUB-PB-22); and
14.15 	(Z) (xvi) methyl N-[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate 
14.16 	(MMB-CHMICA).
14.17 	(i) A controlled substance analog, to the extent that it is implicitly or explicitly intended 
14.18 	for human consumption.

14.19 	EFFECTIVE DATE. This section is effective the day following final enactment.

14.20 	Sec. 2. Minnesota Statutes 2018, section 152.02, subdivision 3, is amended to read:
14.21 		Subd. 3.Schedule II. (a) Schedule II consists of the substances listed in this subdivision.
14.22 	(b) Unless specifically excepted or unless listed in another schedule, any of the following 
14.23 	substances whether produced directly or indirectly by extraction from substances of vegetable 
14.24 	origin or independently by means of chemical synthesis, or by a combination of extraction 
14.25 	and chemical synthesis:
14.26 	(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or 
14.27 	opiate.
14.28 	(i) Excluding:
14.29 	(A) apomorphine;
14.30 	(B) thebaine-derived butorphanol;
15.1 	(C) dextrophan;
15.2 	(D) nalbuphine;
15.3 	(E) nalmefene;
15.4 	(F) naloxegol;
15.5 	(G) naloxone;
15.6 	(H) naltrexone; and
15.7 	(I) their respective salts;
15.8 	(ii) but including the following:
15.9 	(A) opium, in all forms and extracts;
15.10 	(B) codeine;
15.11 	(C) dihydroetorphine;
15.12 	(D) ethylmorphine;
15.13 	(E) etorphine hydrochloride;
15.14 	(F) hydrocodone;
15.15 	(G) hydromorphone;
15.16 	(H) metopon;
15.17 	(I) morphine;
15.18 	(J) oxycodone;
15.19 	(K) oxymorphone;
15.20 	(L) thebaine;
15.21 	(M) oripavine;
15.22 	(2) any salt, compound, derivative, or preparation thereof which is chemically equivalent 
15.23 	or identical with any of the substances referred to in clause (1), except that these substances 
15.24 	shall not include the isoquinoline alkaloids of opium;
15.25 	(3) opium poppy and poppy straw;
15.26 	(4) coca leaves and any salt, cocaine compound, derivative, or preparation of coca leaves 
15.27 	(including cocaine and ecgonine and their salts, isomers, derivatives, and salts of isomers 
15.28 	and derivatives), and any salt, compound, derivative, or preparation thereof which is 
16.1 	chemically equivalent or identical with any of these substances, except that the substances 
16.2 	shall not include decocainized coca leaves or extraction of coca leaves, which extractions 
16.3 	do not contain cocaine or ecgonine;
16.4 	(5) concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid, 
16.5 	or powder form which contains the phenanthrene alkaloids of the opium poppy).
16.6 	(c) Any of the following opiates, including their isomers, esters, ethers, salts, and salts 
16.7 	of isomers, esters and ethers, unless specifically excepted, or unless listed in another schedule, 
16.8 	whenever the existence of such isomers, esters, ethers and salts is possible within the specific 
16.9 	chemical designation:
16.10 	(1) alfentanil;
16.11 	(2) alphaprodine;
16.12 	(3) anileridine;
16.13 	(4) bezitramide;
16.14 	(5) bulk dextropropoxyphene (nondosage forms);
16.15 	(6) carfentanil;
16.16 	(7) dihydrocodeine;
16.17 	(8) dihydromorphinone;
16.18 	(9) diphenoxylate;
16.19 	(10) fentanyl;
16.20 	(11) isomethadone;
16.21 	(12) levo-alpha-acetylmethadol (LAAM);
16.22 	(13) levomethorphan;
16.23 	(14) levorphanol;
16.24 	(15) metazocine;
16.25 	(16) methadone;
16.26 	(17) methadone - intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
16.27 	(18) moramide - intermediate, 2-methyl-3-morpholino-1, 1-diphenyl-propane-carboxylic 
16.28 	acid;
16.29 	(19) pethidine;
17.1 	(20) pethidine - intermediate - a, 4-cyano-1-methyl-4-phenylpiperidine;
17.2 	(21) pethidine - intermediate - b, ethyl-4-phenylpiperidine-4-carboxylate;
17.3 	(22) pethidine - intermediate - c, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
17.4 	(23) phenazocine;
17.5 	(24) piminodine;
17.6 	(25) racemethorphan;
17.7 	(26) racemorphan;
17.8 	(27) remifentanil;
17.9 	(28) sufentanil;
17.10 	(29) tapentadol;
17.11 	(30) 4-Anilino-N-phenethyl-4-piperidine (ANPP).
17.12 	(d) Unless specifically excepted or unless listed in another schedule, any material, 
17.13 	compound, mixture, or preparation which contains any quantity of the following substances 
17.14 	having a stimulant effect on the central nervous system:
17.15 	(1) amphetamine, its salts, optical isomers, and salts of its optical isomers;
17.16 	(2) methamphetamine, its salts, isomers, and salts of its isomers;
17.17 	(3) phenmetrazine and its salts;
17.18 	(4) methylphenidate;
17.19 	(5) lisdexamfetamine.
17.20 	(e) Unless specifically excepted or unless listed in another schedule, any material, 
17.21 	compound, mixture, or preparation which contains any quantity of the following substances 
17.22 	having a depressant effect on the central nervous system, including its salts, isomers, and 
17.23 	salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible 
17.24 	within the specific chemical designation:
17.25 	(1) amobarbital;
17.26 	(2) glutethimide;
17.27 	(3) secobarbital;
17.28 	(4) pentobarbital;
17.29 	(5) phencyclidine;
18.1 	(6) phencyclidine immediate precursors:
18.2 	(i) 1-phenylcyclohexylamine;
18.3 	(ii) 1-piperidinocyclohexanecarbonitrile;
18.4 	(7) phenylacetone.
18.5 	(f) Hallucinogenic substances: nabilone.
18.6 	(g) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless specifically 
18.7 	excepted or unless listed in another schedule, any natural or synthetic material, compound, 
18.8 	mixture, or preparation that contains any quantity of the following substances, their analogs, 
18.9 	isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence 
18.10 	of the isomers, esters, ethers, or salts is possible:
18.11 	(1) marijuana; and
18.12 	(2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, synthetic 
18.13 	equivalents of the substances contained in the cannabis plant or in the resinous extractives 
18.14 	of the plant, or synthetic substances with similar chemical structure and pharmacological 
18.15 	activity to those substances contained in the plant or resinous extract, including but not 
18.16 	limited to 1 cis or trans tetrahydrocannabinol, 6 cis or trans tetrahydrocannabinol, and 3,4 
18.17 	cis or trans tetrahydrocannabinol.

18.18 	EFFECTIVE DATE. This section is effective the day following final enactment.